Nitrates and other nitric oxide donors in cardiology - Current positioning and perspectives

Cardiovascular Drugs and Therapy

Volumn 26, Issue 1, 2012, Pages 55-69

  Iachini Bellisarii, Francesco ^a   Radico, Francesco ^a   Muscente, Francesca ^a   Horowitz, John ^b   De Caterina, Raffaele ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Endothelial dysfunction; Guidelines; Nitrate tolerance; Nitrates; Nitric oxide (NO) donors; Oxidative stress; Preconditioning

Indexed keywords

ACETYLCYSTEINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; GLYCERYL TRINITRATE; HYDRALAZINE; ISOSORBIDE; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE; LISINOPRIL; MOLSIDOMINE; MORPHINE; NESIRITIDE; NICORANDIL; NITRATE; NITRIC ACID DERIVATIVE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PENTAERYTHRITYL TETRANITRATE PLUS RESERPINE; PLACEBO; PRAZOSIN; VERAPAMIL;

ANGINA PECTORIS; AORTA DISSECTION; BIOCHEMISTRY; CARDIOLOGY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESEARCH; DRUG TOLERABILITY; DRUG TRANSFORMATION; ENZYME INHIBITION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; LUNG EDEMA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; SYNDROME X; UNSTABLE ANGINA PECTORIS; VALVULAR HEART DISEASE;

CARDIOVASCULAR DISEASES; EUROPE; HUMANS; NITRATES; NITRIC OXIDE DONORS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84857783988     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6354-0     Document Type: Review

References (90)

1. J Abrams 1995 The role of nitrates in coronary heart disease Arch Intern Med 155 357 64 7848018 10.1001/archinte.1995.00430040023003 1:CAS:528: DyaK2MXkvVWnsb4%3D
2. JA Bauer BP Booth HL Fung 1995 Nitric oxide donors: biochemical pharmacology and therapeutics Adv Pharmacol 34 361 81 8562446 10.1016/S1054-3589(08)61098-4 1:CAS:528:DyaK28XmvVKisg%3D%3D
3. R De Caterina 1991 Antiplatelet effects of nitrate derivatives G Ital Cardiol 21 529 41 1936757
4. T Gori JD Parker 2002 The puzzle of nitrate tolerance: pieces smaller than we thought? Circulation 106 2404 8 12403674 10.1161/01.CIR.0000036742. 52907.91 (Pubitemid 35244745)
5. T Munzel A Daiber A Mulsch 2005 Explaining the phenomenon of nitrate tolerance Circ Res 97 618 28 16195486 10.1161/01.RES.0000184694.03262.6d (Pubitemid 41416330)
6. B Dawn R Bolli 2002 Role of nitric oxide in myocardial preconditioning Ann N Y Acad Sci 962 18 41 12076960 10.1111/j.1749-6632.2002.tb04053.x 1:CAS:528:DC%2BD38XltFalt78%3D (Pubitemid 34592297)
7. H Jneid M Chandra M Alshaher, et al. 2005 Delayed preconditioning-mimetic actions of nitroglycerin in patients undergoing exercise tolerance tests Circulation 111 2565 71 15897341 10.1161/CIRCULATIONAHA.104.515445 1:CAS:528:DC%2BD2MXkt1Shsb0%3D (Pubitemid 40740854)
8. T Gori G Di Stolfo S Sicuro, et al. 2007 Nitroglycerin protects the endothelium from ischaemia and reperfusion: human mechanistic insight Br J Clin Pharmacol 64 145 50 17324239 10.1111/j.1365-2125.2007.02864.x 1:CAS:528:DC%2BD2sXpslGltrg%3D (Pubitemid 47063243)
9. Effect of nicorandil on coronary events in patients with stable angina 2002 the Impact Of Nicorandil in Angina (IONA) randomised trial Lancet 359 1269 75 10.1016/S0140-6736(02)08265-X (Pubitemid 34310631)
10. T Gori JD Parker 2008 Nitrate-induced toxicity and preconditioning: a rationale for reconsidering the use of these drugs J Am Coll Cardiol 52 251 4 18634978 10.1016/j.jacc.2008.04.019 1:CAS:528:DC%2BD1cXoslWmtL8%3D (Pubitemid 351957846)
11. Y Nakamura A Moss M Brown M Kinoshita C Kawai 1999 Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group Am Heart J 138 577 85 10467211 10.1016/S0002-8703(99)70163-8 1:STN:280:DyaK1Mzpsl2isA%3D%3D (Pubitemid 29428783)
12. Z Chen J Zhang J Stamler 2002 Identification of the enzymatic mechanism of nitroglycerin bioactivation Proc Natl Acad Sci USA 99 8306 11 12048254 10.1073/pnas.122225199 1:CAS:528:DC%2BD38XkvVGgsb0%3D (Pubitemid 34651048)
13. S Katsuki F Murad 1977 Regulation of adenosine cyclic 3',5'-monophosphate and guanosine cyclic 3',5'-monophosphate levels and contractility in bovine tracheal smooth muscle Mol Pharmacol 13 330 41 16208 1:CAS:528: DyaE2sXhsFehsLo%3D (Pubitemid 8076777)
14. J Loscalzo 1985 N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin J Clin Invest 76 703 8 2863286 10.1172/JCI112024 1:CAS:528:DyaL2MXltlCrt78%3D (Pubitemid 15023125)
15. RH Zhou WH Frishman 2010 The antiplatelet effects of nitrates: is it of clinical significance in patients with cardiovascular disease? Cardiol Rev 18 198 203 20539103 10.1097/CRD.0b013e3181d74582
16. M Zimarino A Ausiello G Contegiacomo, et al. 2006 Rapid decline of collateral circulation increases susceptibility to myocardial ischemia: the trade-off of successful percutaneous recanalization of chronic total occlusions J Am Coll Cardiol 48 59 65 16814649 10.1016/j.jacc.2005.12.079 (Pubitemid 43929224)
17. P Caramori A Adelman E Azevedo G Newton A Parker J Parker 1998 Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine J Am Coll Cardiol 32 1969 74 9857880 10.1016/S0735-1097(98)00456-2 1:CAS:528:DyaK1MXht1Sj (Pubitemid 29010463)
18. M Kurz K Lamping J Bates C Eastham M Marcus D Harrison 1991 Mechanisms responsible for the heterogeneous coronary microvascular response to nitroglycerin Circ Res 68 847 55 1742870 1:CAS:528:DyaK3MXkt1WlsrY%3D
19. WM Fam M McGregor 1968 Effect of nitroglycerin and dipyridamole on regional coronary resistance Circ Res 22 649 59 4967491 1:CAS:528: DyaF1cXktVWlsbY%3D
20. YY Chirkov JD Horowitz 2007 Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier? Pharmacol Ther 116 287 305 17765975 10.1016/j.pharmthera.2007.06.012 1:CAS:528:DC%2BD2sXhtFSltLjJ (Pubitemid 47451509)
21. YY Chirkov AS Holmes SR Willoughby, et al. 2001 Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets J Am Coll Cardiol 37 1851 7 11401122 10.1016/S0735-1097(01)01238-4 1:CAS:528:DC%2BD3MXltVGhsLg%3D (Pubitemid 32499970)
22. YY Chirkov AS Holmes JD Martelli JD Horowitz 2004 Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction Am J Cardiol 93 1438 40 15165936 10.1016/j.amjcard.2004.02.052 1:CAS:528:DC%2BD2cXksVGgsL4%3D A10 (Pubitemid 38692483)
23. G Cotter E Metzkor E Kaluski, et al. 1998 Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema Lancet 351 389 93 9482291 10.1016/S0140-6736(97)08417-1 1:CAS:528:DyaK1cXhtV2qs74%3D (Pubitemid 28064161)
24. U Thadani 1997 Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure Cardiovasc Drugs Ther 10 735 42 9110117 10.1007/BF00053031 1:STN:280:DyaK2s3msVamtw%3D%3D (Pubitemid 27129777)
25. JD Horowitz 2003 Amelioration of nitrate tolerance: matching strategies with mechanisms J Am Coll Cardiol 41 2001 3 12798572 10.1016/S0735-1097(03) 00399-1 1:CAS:528:DC%2BD3sXltFGjs78%3D (Pubitemid 36677122)
26. PR Sage IS de la Lande I Stafford, et al. 2000 Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion Circulation 102 2810 5 11104737 1:CAS:528:DC%2BD3cXptVSjtr0%3D
27. T Munzel A Daiber T Gori 2011 Nitrate therapy: new aspects concerning molecular action and tolerance Circulation 123 2132 44 21576678 10.1161/CIRCULATIONAHA.110.981407
28. JF Towell 3rd JJ Barboriak WF Townsend JH Kalbfleisch RI Wang 1986 Erythrocyte aldehyde dehydrogenase: assay of a potential biochemical marker of alcohol abuse Clin Chem 32 734 8 3698263 1:CAS:528:DyaL28XktVWkt7o%3D (Pubitemid 17028339)
29. IS Mackenzie KM Maki-Petaja CM McEniery, et al. 2005 Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans Arterioscler Thromb Vasc Biol 25 1891 5 16051882 10.1161/01.ATV.0000179599. 71086.89 1:CAS:528:DC%2BD2MXos1ersbk%3D (Pubitemid 41243459)
30. D'Souza Y, Dowlatshahi S, Bennett BM. Changes in Aldehyde Dehydrogenase 2 Expression in Rat Blood Vessels during Glyceryl Trinitrate Tolerance Development and Reversal. Br J Pharmacol 2011.
31. A Uxa GR Thomas T Gori JD Parker 2010 Standard versus low-dose transdermal nitroglycerin: differential effects on the development of tolerance and abnormalities of endothelial function J Cardiovasc Pharmacol 56 354 9 20588187 10.1097/FJC.0b013e3181ed2dae 1:CAS:528:DC%2BC3cXht1Grs77J
32. PJ Henry OH Drummer JD Horowitz 1989 S-nitrosothiols as vasodilators: implications regarding tolerance to nitric oxide-containing vasodilators Br J Pharmacol 98 757 66 2511992 1:CAS:528:DyaL1MXmt1Gjt78%3D (Pubitemid 19269798)
33. T Gori A Daiber 2009 Non-hemodynamic effects of organic nitrates and the distinctive characteristics of pentaerithrityl tetranitrate Am J Cardiovasc Drugs 9 7 15 19178128 1:CAS:528:DC%2BD1MXjslKqt7o%3D
34. U Thadani 1992 Role of nitrates in angina pectoris Am J Cardiol 70 43B 53B 1529926 10.1016/0002-9149(92)90593-N 1:STN:280:DyaK38vhtFWktA%3D%3D
35. R Gibbons J Abrams K Chatterjee 2003 ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-Summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina) J Am Coll Cardiol 41 159 68 12570960 10.1016/S0735-1097(02)02848-6 (Pubitemid 36044419)
36. K Fox MA Garcia D Ardissino, et al. 2006 Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology Eur Heart J 27 1341 81 16735367 10.1093/eurheartj/ehl001 (Pubitemid 43998110)
37. Y Izumiya S Kojima S Araki, et al. 2011 Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris Atherosclerosis 214 415 21 21168844 10.1016/j.atherosclerosis.2010.11.032 1:CAS:528:DC%2BC3MXhtlKmtL4%3D
38. JL Anderson CD Adams EM Antman, et al. 2007 ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine Circulation 116 e148 304 17679616 10.1161/CIRCULATIONAHA.107.181940
39. H Yamabe H Namura T Yano, et al. 1995 Effect of nicorandil on abnormal coronary flow reserve assessed by exercise 201Tl scintigraphy in patients with angina pectoris and nearly normal coronary arteriograms Cardiovasc Drugs Ther 9 755 61 8850379 10.1007/BF00879868 1:STN:280:DyaK2s%2FgtlSnsg%3D%3D (Pubitemid 26058945)
40. M Zimarino F Prati E Stabile, et al. 2007 Optical coherence tomography accurately identifies intermediate atherosclerotic lesions-an in vivo evaluation in the rabbit carotid artery Atherosclerosis 193 94 101 17007862 10.1016/j.atherosclerosis.2006.08.047 1:CAS:528:DC%2BD2sXlvFamtb0%3D (Pubitemid 46776714)
41. S Silber P Albertsson FF Aviles 2005 Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur Heart J 26 804 47 15769784 10.1093/eurheartj/ehi564
42. J Franciosa S Goldsmith J Cohn 1980 Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure Am J Med 69 559 66 7424945 10.1016/0002-9343(80)90468-4 1:STN:280: DyaL3M%2Fjs1ygsw%3D%3D (Pubitemid 10018711)
43. C Leier P Huss R Magorien D Unverferth 1983 Improved execise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure Circulation 67 817 22 6337742 10.1161/01.CIR.67.4.817 1:STN:280:DyaL3s7ivFyqtg%3D%3D (Pubitemid 13161460)
44. JN Cohn DG Archibald S Ziesche, et al. 1986 Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study N Engl J Med 314 1547 52 3520315 10.1056/NEJM198606123142404 1:STN:280:DyaL283jtVOjtw%3D%3D (Pubitemid 16114684)
45. JN Cohn G Johnson S Ziesche, et al. 1991 A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure N Engl J Med 325 303 10 2057035 10.1056/NEJM199108013250502 1:STN:280:DyaK3M3nvV2gtg%3D%3D
46. TS Rector G Johnson WB Dunkman 1993 Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group Circulation 87 VI71 7 8500243 1:STN:280:DyaK3s3nt1Cgug%3D%3D
47. AL Taylor S Ziesche C Yancy, et al. 2004 Combination of isosorbide dinitrate and hydralazine in blacks with heart failure N Engl J Med 351 2049 57 15533851 10.1056/NEJMoa042934 1:CAS:528:DC%2BD2cXpslegsrs%3D (Pubitemid 39482498)
48. T Munzel H Sayegh BA Freeman MM Tarpey DG Harrison 1995 Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance J Clin Invest 95 187 94 7814613 10.1172/JCI117637 1:STN:280:DyaK2M7hsVWjtA%3D%3D
49. A Daiber M Oelze M Coldewey, et al. 2005 Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure Biochem Biophys Res Commun 338 1865 74 16289107 10.1016/j.bbrc.2005.10.106 1:CAS:528:DC%2BD2MXht1Ggu77F (Pubitemid 41643103)
50. SA Hunt WT Abraham MH Chin, et al. 2005 ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society Circulation 112 e154 235 16160202 10.1161/CIRCULATIONAHA.105.167586
51. K Dickstein A Cohen-Solal G Filippatos, et al. 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J 29 2388 442 18799522 10.1093/eurheartj/ehn309 1:CAS:528:DC%2BD1cXhtlGisbvO
52. A Vahanian H Baumgartner J Bax, et al. 2007 Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology Eur Heart J 28 230 68 17259184 (Pubitemid 46276943)
53. RO Bonow BA Carabello K Chatterjee, et al. 2008 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation 118 e523 661 18820172 10.1161/CIRCULATIONAHA.108.190748
54. NL DePace IM Herling MN Kotler AH Hakki SR Spielman BL Segal 1982 Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action Arch Intern Med 142 1806 9 6812520 10.1001/archinte.1982. 00340230046009 1:STN:280:DyaL3s%2FitFCrtA%3D%3D (Pubitemid 12036213)
55. GS Roubin PJ Harris I Eckhardt W Hensley DT Kelly 1982 Intravenous nitroglycerine in refractory unstable angina pectoris Aust N Z J Med 12 598 602 6819846 10.1111/j.1445-5994.1982.tb02645.x 1:STN:280:DyaL3s7lt1Kqsw%3D%3D (Pubitemid 13131714)
56. S Yusuf R Collins S MacMahon R Peto 1988 Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials Lancet 1 1088 92 2896919 10.1016/S0140-6736(88)91906-X 1:STN:280:DyaL1c3hsFOksQ%3D%3D
57. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343:1115-22.
58. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669-85.
59. JG Cleland 1995 ISIS-4 study Lancet 345 1372 3 7752785 1:STN:280:DyaK2M3nt1aktA%3D%3D author reply 4-5
60. U Thadani 1997 Oral nitrates: more than symptomatic therapy in coronary artery disease? Cardiovasc Drugs Ther 11 Suppl 1 213 8 9211013 10.1023/A:1007750706831 1:CAS:528:DyaK2sXotVCltb8%3D (Pubitemid 27229316)
61. G Cotter H Faibel P Barash, et al. 1998 High-dose nitrates in the immediate management of unstable angina: optimal dosage, route of administration, and therapeutic goals Am J Emerg Med 16 219 24 9596418 10.1016/S0735-6757(98)90087-0 1:STN:280:DyaK1c3lsFymtQ%3D%3D (Pubitemid 28217872)
62. JP Bassand CW Hamm D Ardissino, et al. 2007 Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes Eur Heart J 28 1598 660 17569677 10.1093/eurheartj/ehm132 1:CAS:528:DC%2BD2sXpslKmtLw%3D (Pubitemid 47355992)
63. JD Horowitz CA Henry ML Syrjanen 1988 Nitroglycerine/N-acetylcysteine in the management of unstable angina pectoris Eur Heart J 9 95 100 3137075 Suppl A
64. EM Antman DT Anbe PW Armstrong, et al. 2004 ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction) Circulation 110 e82 292 15339869 10.1161/01.CIR.0000134791.68010.FA (Pubitemid 39036178)
65. EM Antman M Hand PW Armstrong, et al. 2008 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee Circulation 117 296 329 18071078 10.1161/CIRCULATIONAHA.107.188209
66. F Van de Werf J Bax A Betriu, et al. 2008 Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology Eur Heart J 29 2909 45 19004841 10.1093/eurheartj/ehn416
67. M Metra JR Teerlink AA Voors, et al. 2009 Vasodilators in the treatment of acute heart failure: what we know, what we don't Heart Fail Rev 14 299 307 19096932 10.1007/s10741-008-9127-5 1:CAS:528:DC%2BD1MXhtlKju73F
68. U Elkayam F Bitar MW Akhter S Khan S Patrus M Derakhshani 2004 Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations J Cardiovasc Pharmacol Ther 9 227 41 15678242 10.1177/107424840400900403 1:CAS:528:DC%2BD2MXhsVagsbg%3D (Pubitemid 40130010)
69. JF Beltrame CJ Zeitz SA Unger, et al. 1998 Nitrate therapy is an alternative to furosemide/morphine therapy in the management of acute cardiogenic pulmonary edema J Card Fail 4 271 9 9924848 10.1016/S1071-9164(98) 90232-9 1:CAS:528:DyaK1MXms1KgtA%3D%3D (Pubitemid 29042613)
70. AV Chobanian GL Bakris HR Black, et al. 2003 Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 1206 52 14656957 10.1161/01.HYP.0000107251.49515. c2 1:CAS:528:DC%2BD3sXpsVGisL4%3D (Pubitemid 37553153)
71. G Mancia G De Backer A Dominiczak, et al. 2007 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 25 1105 87 17563527 10.1097/HJH.0b013e3281fc975a 1:CAS:528:DC%2BD2sXmtlWnsr0%3D (Pubitemid 46924065)
72. R Erbel F Alfonso C Boileau, et al. 2001 Diagnosis and management of aortic dissection Eur Heart J 22 1642 81 11511117 10.1053/euhj.2001.2782 1:STN:280:DC%2BD3Mvms1Cnsw%3D%3D (Pubitemid 32896367)
73. E Murphy 2004 Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection Circ Res 94 7 16 14715531 10.1161/01.RES.0000108082.76667.F4 1:CAS:528:DC%2BD2cXhtFWn (Pubitemid 38064093)
74. P Needleman 1970 Tolerance to the vascular effects of glyceryl trinitrate J Pharmacol Exp Ther 171 98 102 4983392 1:CAS:528:DyaE3cXktFCltQ%3D%3D
75. WD Bussmann D Passek W Seidel M Kaltenbach 1981 Reduction of CK and CK-MB indexes of infarct size by intravenous nitroglycerin Circulation 63 615 22 6780232 10.1161/01.CIR.63.3.615 1:STN:280:DyaL3M7ht1GrtA%3D%3D (Pubitemid 11139871)
76. BI Jugdutt JW Warnica 1988 Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location Circulation 78 906 19 3139326 10.1161/01.CIR.78.4.906 1:STN:280:DyaL1M%2FgtlGjtA%3D%3D
77. K Ishikawa K Kanamasa I Ogawa, et al. 1996 Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction Secondary Prevention Group. Jpn Circ J 60 779 88 1:CAS:528:DyaK2sXjtVWhtw%3D%3D
78. K Kanamasa N Naito H Morii, et al. 2004 Eccentric dosing of nitrates does not increase cardiac events in patients with healed myocardial infarction Hypertens Res 27 563 72 15492476 10.1291/hypres.27.563 1:CAS:528: DC%2BD2cXhtVKntbrK (Pubitemid 39341155)
79. MT La Rovere GD Pinna SH Hohnloser, et al. 2001 Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials Circulation 103 2072 7 11319197 (Pubitemid 32373010)
80. T Gori JS Floras JD Parker 2002 Effects of nitroglycerin treatment on baroreflex sensitivity and short-term heart rate variability in humans J Am Coll Cardiol 40 2000 5 12475461 10.1016/S0735-1097(02)02532-9 1:CAS:528: DC%2BD3sXnslSi (Pubitemid 35425368)
81. D Ardissino PA Merlini S Savonitto, et al. 1997 Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris J Am Coll Cardiol 29 941 7 9120179 10.1016/S0735- 1097(97)00005-3 1:CAS:528:DyaK2sXislamsLo%3D (Pubitemid 27149565)
82. JD Horowitz CA Henry ML Syrjanen, et al. 1988 Combined use of nitroglycerin and N-acetylcysteine in the management of unstable angina pectoris Circulation 77 787 94 3127076 10.1161/01.CIR.77.4.787 1:STN:280: DyaL1c7msFCguw%3D%3D (Pubitemid 18093499)
83. H DeMots SP Glasser 1989 Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina J Am Coll Cardiol 13 786 95 2494240 10.1016/0735-1097(89)90216-7 1:STN:280:DyaL1M7nsFyitw%3D%3D
84. JD Parker 1998 Nitrate therapy for stable angina pectoris N Eng J Med 338 520 31 10.1056/NEJM199802193380807 1:CAS:528:DyaK1cXhsVGju7g%3D (Pubitemid 28103137)
85. JB Laursen M Somers S Kurz, et al. 2001 Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin Circulation 103 1282 8 11238274 1:CAS:528:DC%2BD3MXisFeksb4%3D (Pubitemid 32221353)
86. N Gruhn J Aldershvile S Boesgaard 2001 Tetrahydrobiopterin improves endothelium-dependent vasodilation in nitroglycerin-tolerant rats Eur J Pharmacol 416 245 9 11290375 10.1016/S0014-2999(01)00879-2 1:CAS:528: DC%2BD3MXisVWmsro%3D (Pubitemid 32274252)
87. T Munzel A Giaid S Kurz DJ Stewart DG Harrison 1995 Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance Proc Natl Acad Sci U S A 92 5244 8 7539147 10.1073/pnas.92.11.5244 1:CAS:528:DyaK2MXlvFyhsr4%3D
88. J Towell T Garthwaite R Wang 1985 Erythrocyte aldehyde dehydrogenase and disulfiram-like side effects of hypoglycemics and antianginals Alcohol Clin Exp Res 9 438 42 3933375 10.1111/j.1530-0277.1985.tb05579.x 1:CAS:528: DyaL2MXlvV2hsLk%3D (Pubitemid 16245575)
89. E Schulz N Tsilimingas R Rinze, et al. 2002 Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment Circulation 105 1170 5 11889009 10.1161/hc1002.105186 1:CAS:528:DC%2BD38XivFaru78%3D (Pubitemid 34225816)
90. SB King 3rd SC Smith Jr JW Hirshfeld Jr, et al. 2008 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee Circulation 117 261 95 18079354 10.1161/CIRCULATIONAHA.107.188208